Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Archives

You are currently viewing the 2000 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NEMBUTAL

« Back to Dashboard

Nembutal is a drug marketed by Oak Pharms and is included in six NDAs.

The generic ingredient in NEMBUTAL is pentobarbital sodium. There are two drug master file entries for this compound. Additional details are available on the pentobarbital sodium profile page.

Summary for Tradename: NEMBUTAL


Clinical Trials for: NEMBUTAL

Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation
Status: Withdrawn Condition: Sedation

Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension
Status: Terminated Condition: Traumatic Brain Injury

Sedation for Brainstem Evoked Auditory Response (BEAR) Testing Using Intravenous Pentobarbital
Status: Completed Condition: Childrens 0 to 18 Years of Age Who Require Moderate Sedation

A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)
Status: Not yet recruiting Condition: Heart Disease

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1
Status: Terminated Condition: Sodium Oxybate; Substance-Related Disorders

Physiological, Behavioral and Subjective Effects of Drugs (GHB)
Status: Completed Condition: Sedative Abuse

Pharmacokinetics and Pharmacodynamics of Pentobarbital in Neonates, Infants, and Children Following Open Heart Surgery
Status: Terminated Condition: Cardiac Surgical Procedures

Treatment of Refractory Status Epilepticus
Status: Terminated Condition: Status Epilepticus

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Status: Completed Condition: Alzheimer's Disease; Huntington's Disease

Mutations in Genes Associated With Pentalogy of Cantrell or Non-Muscle Myosin II Syndromes
Status: Recruiting Condition: Inborn Genetic Diseases; Pentalogy of Cantrell

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
pentobarbital sodium
Injectable; Injection083246Approved prior to Jan 1, 1982RXYes<disabled><disabled>
Elixir; Oral083244Approved prior to Jan 1, 1982RXYes<disabled><disabled>
pentobarbital sodium
Capsule; Oral083245Approved prior to Jan 1, 1982RXYes<disabled><disabled>
pentobarbital sodium
Capsule; Oral084093Approved prior to Jan 1, 1982RXYes<disabled><disabled>
pentobarbital sodium
Capsule; Oral084095Approved prior to Jan 1, 1982RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology